Literature DB >> 23774862

Limited role of the receptor for advanced glycation end products during Streptococcus pneumoniae bacteremia.

Ahmed Achouiti1, Alex F de Vos, Regina de Beer, Sandrine Florquin, Cornelis van 't Veer, Tom van der Poll.   

Abstract

Streptococcus pneumoniae is one of the most common causes of sepsis. Sepsis is associated with the release of 'damage-associated molecular patterns' (DAMPs). The receptor for advanced glycation end products (RAGE) is a multiligand receptor, abundantly expressed in the lungs, that recognizes several of these DAMPs. Triggering of RAGE leads to activation of the NF-κB pathway and perpetuation of inflammation. Earlier investigations have shown that the absence of RAGE reduces inflammation and bacterial dissemination and increases survival in sepsis caused by S. pneumoniae pneumonia. We hypothesized that the detrimental role of RAGE depends on the level of RAGE expression in the primary organ of infection. By directly injecting S. pneumoniae intravenously, thereby circumventing the extensive RAGE-expressing lung, we here determined whether RAGE contributes to an adverse outcome of bacteremia or whether its role is restricted to primary lung infection. During late-stage infection (48 h), rage(-/-) mice had an attenuated systemic inflammatory response, as reflected by lower plasma levels of proinflammatory cytokines, reduced endothelial cell activation (as measured by E-selectin levels) and less neutrophil accumulation in lung tissue. However, RAGE deficiency did not influence bacterial loads or survival in this model. In accordance, plasma markers for cell injury were similar in both mouse strains. These results demonstrate that while RAGE plays a harmful part in S. pneumoniae sepsis originating from the respiratory tract, this receptor has a limited role in the outcome of primary bloodstream infection by this pathogen.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23774862      PMCID: PMC6741477          DOI: 10.1159/000348739

Source DB:  PubMed          Journal:  J Innate Immun        ISSN: 1662-811X            Impact factor:   7.349


  6 in total

1.  RAGE-Mediated Suppression of Interleukin-10 Results in Enhanced Mortality in a Murine Model of Acinetobacter baumannii Sepsis.

Authors:  Michael J Noto; Kyle W Becker; Kelli L Boyd; Ann Marie Schmidt; Eric P Skaar
Journal:  Infect Immun       Date:  2017-02-23       Impact factor: 3.441

2.  DNA-Aptamer Raised against Receptor for Advanced Glycation End Products Improves Survival Rate in Septic Mice.

Authors:  Yoshinori Koga; Ami Sotokawauchi; Yuichiro Higashimoto; Yuri Nishino; Naoki Hashizume; Tatsuyuki Kakuma; Jun Akiba; Yoshiaki Tanaka; Takanori Matsui; Minoru Yagi; Sho-Ichi Yamagishi
Journal:  Oxid Med Cell Longev       Date:  2021-08-07       Impact factor: 6.543

3.  Hematopoietic but not endothelial cell MyD88 contributes to host defense during gram-negative pneumonia derived sepsis.

Authors:  Miriam H P van Lieshout; Adam A Anas; Sandrine Florquin; Baidong Hou; Cornelis van't Veer; Alex F de Vos; Tom van der Poll
Journal:  PLoS Pathog       Date:  2014-09-25       Impact factor: 6.823

4.  RAGE Deficiency Impairs Bacterial Clearance in Murine Staphylococcal Sepsis, but Has No Significant Impact on Staphylococcal Septic Arthritis.

Authors:  Majd Mohammad; Manli Na; Amanda Welin; Mattias N D Svensson; Abukar Ali; Tao Jin; Rille Pullerits
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240

5.  Classically activated mouse macrophages produce methylglyoxal that induces a TLR4- and RAGE-independent proinflammatory response.

Authors:  Daniel Prantner; Shreeram Nallar; Katharina Richard; David Spiegel; Kim D Collins; Stefanie N Vogel
Journal:  J Leukoc Biol       Date:  2020-07-17       Impact factor: 4.962

Review 6.  The impact of RAGE inhibition in animal models of bacterial sepsis: a systematic review and meta-analysis.

Authors:  Xin Zhao; Yan-Nian Liao; Qian Huang
Journal:  J Int Med Res       Date:  2017-07-31       Impact factor: 1.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.